BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 15819840)

  • 1. Estimating resource use and cost of prophylactic management of neutropenia with filgrastim.
    Annemans L; Van Overbeke N; Standaert B; Van Belle S
    J Nurs Manag; 2005 May; 13(3):265-74. PubMed ID: 15819840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy.
    Tan Sean P; Chouaid C; Hettler D; Baud M; Hejblum G; Tilleul P
    Curr Med Res Opin; 2009 Jun; 25(6):1455-60. PubMed ID: 19419340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients.
    Bennett CL; Calhoun EA
    Oncologist; 2007 Apr; 12(4):478-83. PubMed ID: 17470690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.
    Cosler LE; Sivasubramaniam V; Agboola O; Crawford J; Dale D; Lyman GH
    Value Health; 2005; 8(1):47-52. PubMed ID: 15841893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of nursing management and utilization of nursing resources with the RAFAELA patient classification system--case study from the general wards of one central hospital.
    Rainio AK; Ohinmaa AE
    J Clin Nurs; 2005 Jul; 14(6):674-84. PubMed ID: 15946275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment.
    Lingaratnam S; Worth LJ; Slavin MA; Bennett CA; Kirsa SW; Seymour JF; Dalton A; Koczwara B; Prince HM; O'Reilly M; Mileshkin L; Szer J; Thursky KA
    Aust Health Rev; 2011 Nov; 35(4):491-500. PubMed ID: 22126955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct costs of warfarin treatment among patients with atrial fibrillation in a Finnish health care setting.
    Hallinen T; Martikainen JA; Soini EJ; Suominen L; Aronkytö T
    Curr Med Res Opin; 2006 Apr; 22(4):683-92. PubMed ID: 16684429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost of the district hospital: a case study in Malawi.
    Mills AJ; Kapalamula J; Chisimbi S
    Bull World Health Organ; 1993; 71(3-4):329-39. PubMed ID: 8324852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of variation in the cost of inpatient stays versus outpatient visits in hospitals: a multi-country analysis.
    Adam T; Evans DB
    Soc Sci Med; 2006 Oct; 63(7):1700-10. PubMed ID: 16769168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of decision analysis to evaluate the costs and benefits of filgrastim (G-CSF) therapy.
    Peroutka JA; Mutnick AH
    Formulary; 1995 Jul; 30(7):394-5, 400-4. PubMed ID: 10151731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Organizational and client determinants of cost in outpatient substance abuse treatment.
    Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
    J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is integrated nursing home care cheaper than traditional care? A cost comparison.
    Paulus AT; van Raak AJ; Maarse HJ
    Int J Nurs Stud; 2008 Dec; 45(12):1764-77. PubMed ID: 18755460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
    Ghatnekar O; Alvegård T; Conradi N; Lenhoff S; Mellqvist UH; Persson U; Löthgren M
    Clin Ther; 2008 Sep; 30(9):1704-13. PubMed ID: 18840377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costing substance misuse services.
    Coyle D; Godfrey C; Hardman G; Raistrick D
    Addiction; 1997 Aug; 92(8):1007-15. PubMed ID: 9376770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Costs of chronic dialysis in a public hospital: myths and realities].
    Lamas J; Alonso M; Saavedra J; García-Trío G; Rionda M; Ameijeiras M
    Nefrologia; 2001; 21(3):283-94. PubMed ID: 11471309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health system costs of out-of-hospital cardiac arrest in relation to time to shock.
    van Alem AP; Dijkgraaf MG; Tijssen JG; Koster RW
    Circulation; 2004 Oct; 110(14):1967-73. PubMed ID: 15381641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection.
    Santolaya ME; Alvarez AM; Avilés CL; Becker A; Cofré J; Cumsille MA; O'Ryan ML; Payá E; Salgado C; Silva P; Tordecilla J; Varas M; Villarroel M; Viviani T; Zubieta M
    J Clin Oncol; 2004 Sep; 22(18):3784-9. PubMed ID: 15365075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the costs of psychiatric hospital services at a public health facility in Nigeria.
    Ezenduka C; Ichoku H; Ochonma O
    J Ment Health Policy Econ; 2012 Sep; 15(3):139-48. PubMed ID: 23001282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost of home and hospital care for patients with cystic fibrosis followed up in two reference medical centers in France.
    Horvais V; Touzet S; François S; Bourdy S; Bellon G; Colin C; Durieu I
    Int J Technol Assess Health Care; 2006; 22(4):525-31. PubMed ID: 16984688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.